Is Sanofi SA (ADR) (NYSE:SNY) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, …
The Company announced on July 11, 2017, its plans to acquire the privately held vaccines biotech Company Protein
Sanofi (SNY) retreated -0.05% to reach at the floor price of $39.44 as the company is set to share its next quarterly earnings on July 29, 2016. SNY stock trades between $39.25 and $39.79 before the earnings release. Let’s take a …
Paris, France - June 15, 2017 - Sanofi announced today the launch of "Action 2017", a worldwide stock purchase plan reserved for its employees. In doing such a capital increase, Sanofi intends to better associate its employees with the …
Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc. announced positive results from two Phase 3b/4 ODYSSEY-DM trials in patients ... Sanofi SA (ADR) (NYSE:SNY) on Monday closed at $47.57. Stock institutional …
Sanofi (NYSE:SNY) hit a new 52-week high Tuesday as it is currently trading at $55.89, above its previous 52-week high of $55.86 with 562,408 shares traded as of 10:40 a.m. ET. Average volume has been 2.4 million shares over the past 30 …
“These data suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults, Sanofi ... The stock’s 50-day moving …
Genzyme argued that the drug Lemtrada's market potential was not being recognized in Sanofi's offering price. After months of back and forth, the two sides agreed on a compromise: a tracking stock that allowed investors to make an …
The drugmaker posted revenue of $9.53 billion in the period. Sanofi shares have risen 18 percent since the beginning of the year. The stock has risen 12 percent in the last 12 months. This story was generated by Automated Insights …
CNBC23d